{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:48:39Z","timestamp":1783129719879,"version":"3.54.6"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012580","name":"Natural Science Foundation of Tianjin Science and Technology Correspondent Project","doi-asserted-by":"publisher","award":["20JCQNJC01570"],"award-info":[{"award-number":["20JCQNJC01570"]}],"id":[{"id":"10.13039\/501100012580","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801998"],"award-info":[{"award-number":["81801998"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31971127"],"award-info":[{"award-number":["31971127"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People&apos;s Republic of China","doi-asserted-by":"publisher","award":["2020YFA0908500"],"award-info":[{"award-number":["2020YFA0908500"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.antiviral.2021.105102","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T03:01:49Z","timestamp":1622516509000},"page":"105102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Reversible covalent inhibitors suppress enterovirus 71 infection by targeting the 3C protease"],"prefix":"10.1016","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9462-9878","authenticated-orcid":false,"given":"Meijun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqing","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3507-3969","authenticated-orcid":false,"given":"Yaxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2021.105102_bib1","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1039\/C9CS00720B","article-title":"Advances in covalent kinase inhibitors","volume":"49","author":"Abdeldayem","year":"2020","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.antiviral.2021.105102_bib2","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1128\/JVI.80.9.4501-4509.2006","article-title":"Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo","volume":"80","author":"Ank","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2021.105102_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrd3620","article-title":"The pharmacological landscape and therapeutic potential of serine hydrolases","volume":"11","author":"Bachovchin","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2021.105102_bib4","doi-asserted-by":"crossref","first-page":"13408","DOI":"10.1002\/anie.201601091","article-title":"Targeted covalent inhibitors for drug design","volume":"55","author":"Baillie","year":"2016","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.antiviral.2021.105102_bib5","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1742-1241.2006.01178.x","article-title":"DPP-4 inhibitors and their potential role in the management of type 2 diabetes","volume":"60","author":"Barnett","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.antiviral.2021.105102_bib6","article-title":"Luteoloside acts as 3C protease inhibitor of enterovirus 71 in vitro","volume":"11","author":"Cao","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2021.105102_bib7","doi-asserted-by":"crossref","first-page":"6406","DOI":"10.1074\/jbc.M111.301622","article-title":"Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2","volume":"287","author":"Chen","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2021.105102_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005165","article-title":"Structure elucidation of coxsackievirus A16 in complex with GPP3 informs a systematic review of highly potent capsid binders to enteroviruses","volume":"11","author":"De Colibus","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2021.105102_bib9","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1021\/jm980068d","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies","volume":"41","author":"Dragovich","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2021.105102_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2019.07.012","article-title":"High proportion of coxsackievirus B3 genotype A in hand, foot and mouth disease in Zhenjiang, China, 2011-2016","volume":"87","author":"Fu","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2021.105102_bib11","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/cr.2015.139","article-title":"Gasdermin D is an executor of pyroptosis and required for interleukin-1 beta secretion","volume":"25","author":"He","year":"2015","journal-title":"Cell Res."},{"key":"10.1016\/j.antiviral.2021.105102_bib12","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1126\/science.1132505","article-title":"5'-Triphosphate RNA is the ligand for RIG-I","volume":"314","author":"Hornung","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2021.105102_bib13","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/jac\/dkp502","article-title":"Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid","volume":"65","author":"Hung","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2021.105102_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cbpa.2017.05.008","article-title":"Covalent inhibitors: an opportunity for rational target selectivity","volume":"39","author":"Lagoutte","year":"2017","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.antiviral.2021.105102_bib15","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1002\/anie.201203341","article-title":"Reversible covalent inhibition of a protein target","volume":"51","author":"Lee","year":"2012","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.antiviral.2021.105102_bib16","doi-asserted-by":"crossref","first-page":"9830","DOI":"10.1128\/JVI.01425-14","article-title":"Enterovirus 71 3C inhibits cytokine expression through cleavage of the TAK1\/TAB1\/TAB2\/TAB3 complex","volume":"88","author":"Lei","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2021.105102_bib17","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1128\/JVI.02491-09","article-title":"The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses","volume":"84","author":"Lei","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2021.105102_bib18","doi-asserted-by":"crossref","first-page":"8811","DOI":"10.1128\/JVI.00447-11","article-title":"Cleavage of the adaptor protein TRIF by enterovirus 71 3C inhibits antiviral responses mediated by Toll-like receptor 3","volume":"85","author":"Lei","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2021.105102_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01069-17","article-title":"Enterovirus 71 inhibits pyroptosis through cleavage of gasdermin D","volume":"91","author":"Lei","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2021.105102_bib20","first-page":"26","article-title":"A novel enterovirus 71 (EV71) virulence determinant: the 69th residue of 3C protease modulates pathogenicity","volume":"7","author":"Li","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.antiviral.2021.105102_bib21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1423-0127-16-103","article-title":"Viral and host proteins involved in picornavirus life cycle","volume":"16","author":"Lin","year":"2009","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.antiviral.2021.105102_bib22","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1039\/C7CS00220C","article-title":"Structure-based design of targeted covalent inhibitors","volume":"47","author":"Lonsdale","year":"2018","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.antiviral.2021.105102_bib23","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ejmech.2016.10.019","article-title":"Identification and biochemical characterization of DC07090 as a novel potent small molecule inhibitor against human enterovirus 71 3C protease by structure-based virtual screening","volume":"124","author":"Ma","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.antiviral.2021.105102_bib24","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1021\/acs.jmedchem.9b00387","article-title":"Application of dually activated Michael acceptor to the rational design of reversible covalent inhibitor for enterovirus 71 3C protease","volume":"62","author":"Ma","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2021.105102_bib25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1586\/14760584.2016.1138862","article-title":"EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD)","volume":"15","author":"Mao","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.antiviral.2021.105102_bib26","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1126\/science.1132998","article-title":"RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates","volume":"314","author":"Pichlmair","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2021.105102_bib27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nchembio.925","article-title":"Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles","volume":"8","author":"Serafimova","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.antiviral.2021.105102_bib28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.antiviral.2012.12.005","article-title":"Antiviral drug discovery for the treatment of enterovirus 71 infections","volume":"97","author":"Shang","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2021.105102_bib29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.tibs.2016.10.004","article-title":"Pyroptosis: gasdermin-mediated programmed necrotic cell death","volume":"42","author":"Shi","year":"2017","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.antiviral.2021.105102_bib30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2021.105102_bib31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.celrep.2015.05.047","article-title":"Reciprocal regulation between enterovirus 71 and the NLRP3 inflammasome","volume":"12","author":"Wang","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.antiviral.2021.105102_bib32","doi-asserted-by":"crossref","first-page":"10021","DOI":"10.1128\/JVI.05107-11","article-title":"Crystal structures of enterovirus 71 3C protease complexed with rupintrivir reveal the roles of catalytically important residues","volume":"85","author":"Wang","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2021.105102_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2017.01.002","article-title":"Inhibition of enterovirus 71 replication by an alpha-hydroxy-nitrile derivative NK-1.9k","volume":"141","author":"Wang","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2021.105102_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00298-17","article-title":"Structure of the enterovirus 71 3C protease in complex with NK-1.8k and indications for the development of antienterovirus protease inhibitor","volume":"61","author":"Wang","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2021.105102_bib35","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1007\/s00284-020-02082-4","article-title":"The function and mechanism of enterovirus 71 (EV71) 3C protease","volume":"77","author":"Wen","year":"2020","journal-title":"Curr. Microbiol."},{"key":"10.1016\/j.antiviral.2021.105102_bib36","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1107\/S0907444913002862","article-title":"Structures of Enterovirus 71 3C proteinase (strain E2004104-TW-CDC) and its complex with rupintrivir","volume":"69","author":"Wu","year":"2013","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.antiviral.2021.105102_bib37","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fmicb.2018.00286","article-title":"Enterovirus A71 proteins: structure and function","volume":"9","author":"Yuan","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.antiviral.2021.105102_bib38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2105-7-85","article-title":"Statistical analysis of real-time PCR data","volume":"7","author":"Yuan","year":"2006","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.antiviral.2021.105102_bib39","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.bmcl.2016.02.039","article-title":"Synthesis and structure\u2013activity relationship of \u03b1-keto amides as enterovirus 71 3C protease inhibitors","volume":"26","author":"Zeng","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2021.105102_bib40","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ejmech.2016.08.064","article-title":"Structure\u2013activity relationship study of peptidomimetic aldehydes as enterovirus 71 3C protease inhibitors","volume":"124","author":"Zhai","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.antiviral.2021.105102_bib41","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1021\/acs.jmedchem.5b01013","article-title":"Cyanohydrin as an anchoring group for potent and selective inhibitors of enterovirus 71 3C protease","volume":"58","author":"Zhai","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2021.105102_bib42","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.antiviral.2012.12.029","article-title":"Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model","volume":"97","author":"Zhang","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2021.105102_bib43","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.ymthe.2020.04.005","article-title":"Enterovirus A71 oncolysis of malignant gliomas","volume":"28","author":"Zhang","year":"2020","journal-title":"Mol. Ther."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354221000929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354221000929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:12:20Z","timestamp":1777497140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354221000929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":43,"alternative-id":["S0166354221000929"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2021.105102","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversible covalent inhibitors suppress enterovirus 71 infection by targeting the 3C protease","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2021.105102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105102"}}